TUCSON, Ariz. – NeuTherapeutics, a Tucson startup founded to commercialize University of Arizona technology has received a $2.5M Small Business Innovation Research (SBIR) grant from the National Institutes of Health/ National Institute on Aging (NIA) to conduct a Phase 2 clinical trial to evaluate the impact of a new dietary supplement, PhytoSERM, on menopausal hot flashes in women.Continue reading
Category Archives: AZBio News
Castle Bioscience CEO Interviewed on Behind the Bell
In this episode of Behind the Bell, Castle Biosciences Founder & CEO Derek J. Maetzold shares the impact of $CSTL being #NasdaqListed on the company’s mission in developing innovative genomic tests. Continue reading
NIA grant supports training of next generation of translational scientists for Alzheimer’s disease therapeutic development
Researchers at the Center for Innovation in Brain Science received a $1.4 million Translational Research in Alzheimer’s Disease and Related Dementias grant.Continue reading
GT Medical Technologies, Inc.’ GammaTile® Therapy Awarded 2023 Most Promising New Product of the Year by The Phoenix: The Medical Device and Diagnostic Conference for Chief Executive Officers
Oct. 13, 2023 /PRNewswire/ — GT Medical Technologies, Inc. a medical device company dedicated to improving the lives of patients with brain tumors, today announced that its FDA-cleared GammaTile® Therapy was awarded the 2023 Most Promising New Product of the Year by The Phoenix: The Medical Device and Diagnostic Conference for Chief Executive Officers. Continue reading
Barrow Neurological Institute receives $16.7 million NIH award to help coordinate new national ALS research consortium
(PHOENIX – Oct. 5, 2023) – Barrow Neurological Institute has received a large award from the National Institutes of Health (NIH) to help create and lead a groundbreaking and transformative national amyotrophic lateral sclerosis (ALS) clinical research consortium. The award is the largest Barrow has ever received from the NIH with a first year budget of $16.7 million.Continue reading
AdvaMed Launches New Digital Health Tech Division, Appoints Board Members
WASHINGTON, D.C. – Today, AdvaMed, the Medtech Association, announced the formation of AdvaMed Digital Health Tech, a new division within the organization that represents digital medical technology companies and promotes the critical role of data and digital medtech in transforming health care. The group, which is led by Shaye Mandle, acts as a thought leader and convener for the industry and focuses on four core policy areas: regulation, payment and health care delivery, data stewardship and privacy, and cybersecurity.
Special Report: FDA’s proposed rule to bring LDTs into the fold
After bringing up the topic many times over the past two decades, the FDA has finally done it: They’ve issued a proposed rule that would eliminate the agency’s enforcement discretion over laboratory-developed tests (LDTs), integrating LDTs into the FDA’s oversight over a period of four years. This issue has been top of mind for the FDA and most everyone in the diagnostics ecosystem for many years. The change has the potential to be a very big deal. Whether for good or bad depends on your viewpoint.Continue reading
HonorHealth Research Institute clinical trial helps secure FDA approval of revolutionary new pacemaker
World’s first dual chamber leadless pacemaker successfully implanted in 22 HonorHealth patients, stimulating two heart chambers without using wiresContinue reading
HonorHealth Research Institute potentially part of 8,000-patient global clinical trial to test drug that might prevent severe bleeding
SCOTTSDALE, Ariz. — Oct. 4, 2023 — HonorHealth Research Institute is consulting the people of Scottsdale and Phoenix about whether to lead a local trauma research study to investigate a blood clotting agent as a treatment for trauma patients who are bleeding to death.Continue reading
Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company
The Spin-off of Sandoz enables Novartis to complete its transformation to become a leading, focused medicines company. With capital allocation and management attention fully focused on innovative medicines, Novartis is well-positioned for sustained top- and bottom-line growth.Continue reading